Correlation Between Esperion Therapeutics and Agios Pharm

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Agios Pharm at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Agios Pharm into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Esperion Therapeutics and Agios Pharm, you can compare the effects of market volatilities on Esperion Therapeutics and Agios Pharm and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Agios Pharm. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Agios Pharm.

Diversification Opportunities for Esperion Therapeutics and Agios Pharm

0.77
  Correlation Coefficient

Poor diversification

The 3 months correlation between Esperion and Agios is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Agios Pharm in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Agios Pharm and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Agios Pharm. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Agios Pharm has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Agios Pharm go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Agios Pharm

Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 1.27 times more return on investment than Agios Pharm. However, Esperion Therapeutics is 1.27 times more volatile than Agios Pharm. It trades about -0.13 of its potential returns per unit of risk. Agios Pharm is currently generating about -0.19 per unit of risk. If you would invest  280.00  in Esperion Therapeutics on November 29, 2024 and sell it today you would lose (115.00) from holding Esperion Therapeutics or give up 41.07% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Esperion Therapeutics  vs.  Agios Pharm

 Performance 
       Timeline  
Esperion Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Agios Pharm 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Agios Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Esperion Therapeutics and Agios Pharm Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Esperion Therapeutics and Agios Pharm

The main advantage of trading using opposite Esperion Therapeutics and Agios Pharm positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Agios Pharm can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will offset losses from the drop in Agios Pharm's long position.
The idea behind Esperion Therapeutics and Agios Pharm pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm